Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS

Elizabeth Cohen-Jonathan, Ruth J. Muschel, W. Gillies McKenna, Sydney M. Evans, George Cerniglia, Rosemarie Mick, Donna Kusewitt, Said M. Sebti, Andrew Hamilton, Allen Oliff, Nancy Kohl, Jackson B. Gibbs, Eric J. Bernhard

Research output: Contribution to journalArticle

Abstract

Successful radiosensitization requires that tumor cells become more radiosensitive without causing an equivalent reduction in the survival of cells of the surrounding normal tissues. Since tumor cell radiosensitivity can be influenced by RAS oncogene activation, we have hypothesized that inhibition of oncogenic RAS activity would lead to radiosensitization of tumors with activated RAS. We previously showed in tissue culture that prenyltransferase treatment of cells with activated RAS resulted in radiosensitization, whereas treatment of cells with wild-type RAS had no effect on radiation survival. Here we ask whether the findings obtained in vitro have applicability in vivo. We found that treatment of nude mice bearing T24 tumor cell xenografts with farnesyltransferase inhibitors resulted in a significant and synergistic reduction in tumor cell survival after irradiation. The regrowth of T24 tumors expressing activated RAS was also significantly prolonged by the addition of treatment with farnesyltransferase inhibitors compared to the regrowth after irradiation alone. In contrast, there was no effect on the radiosensitivity of HT-29 tumors expressing wild-type RAS. These results demonstrate that specific radiosensitization of tumors expressing activated RAS oncogenes can be obtained in vivo. (C) 2000 by Radiation Research Society.

Original languageEnglish (US)
Pages (from-to)125-132
Number of pages8
JournalRadiation Research
Volume154
Issue number2
StatePublished - Aug 2000

Fingerprint

Farnesyltranstransferase
Radiation Effects
Heterografts
inhibitors
tumors
neoplasms
oncogenes
radiation
regrowth
cell viability
Neoplasms
irradiation
Radiation Tolerance
radiation tolerance
Oncogenes
tissue culture
Cell Survival
Dimethylallyltranstransferase
cells
neoplasm cells

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Radiology Nuclear Medicine and imaging
  • Biophysics
  • Radiation

Cite this

Cohen-Jonathan, E., Muschel, R. J., McKenna, W. G., Evans, S. M., Cerniglia, G., Mick, R., ... Bernhard, E. J. (2000). Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiation Research, 154(2), 125-132.

Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. / Cohen-Jonathan, Elizabeth; Muschel, Ruth J.; McKenna, W. Gillies; Evans, Sydney M.; Cerniglia, George; Mick, Rosemarie; Kusewitt, Donna; Sebti, Said M.; Hamilton, Andrew; Oliff, Allen; Kohl, Nancy; Gibbs, Jackson B.; Bernhard, Eric J.

In: Radiation Research, Vol. 154, No. 2, 08.2000, p. 125-132.

Research output: Contribution to journalArticle

Cohen-Jonathan, E, Muschel, RJ, McKenna, WG, Evans, SM, Cerniglia, G, Mick, R, Kusewitt, D, Sebti, SM, Hamilton, A, Oliff, A, Kohl, N, Gibbs, JB & Bernhard, EJ 2000, 'Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS', Radiation Research, vol. 154, no. 2, pp. 125-132.
Cohen-Jonathan E, Muschel RJ, McKenna WG, Evans SM, Cerniglia G, Mick R et al. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiation Research. 2000 Aug;154(2):125-132.
Cohen-Jonathan, Elizabeth ; Muschel, Ruth J. ; McKenna, W. Gillies ; Evans, Sydney M. ; Cerniglia, George ; Mick, Rosemarie ; Kusewitt, Donna ; Sebti, Said M. ; Hamilton, Andrew ; Oliff, Allen ; Kohl, Nancy ; Gibbs, Jackson B. ; Bernhard, Eric J. / Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. In: Radiation Research. 2000 ; Vol. 154, No. 2. pp. 125-132.
@article{e5d8eb6c498e4a45917fda3c844f0b88,
title = "Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS",
abstract = "Successful radiosensitization requires that tumor cells become more radiosensitive without causing an equivalent reduction in the survival of cells of the surrounding normal tissues. Since tumor cell radiosensitivity can be influenced by RAS oncogene activation, we have hypothesized that inhibition of oncogenic RAS activity would lead to radiosensitization of tumors with activated RAS. We previously showed in tissue culture that prenyltransferase treatment of cells with activated RAS resulted in radiosensitization, whereas treatment of cells with wild-type RAS had no effect on radiation survival. Here we ask whether the findings obtained in vitro have applicability in vivo. We found that treatment of nude mice bearing T24 tumor cell xenografts with farnesyltransferase inhibitors resulted in a significant and synergistic reduction in tumor cell survival after irradiation. The regrowth of T24 tumors expressing activated RAS was also significantly prolonged by the addition of treatment with farnesyltransferase inhibitors compared to the regrowth after irradiation alone. In contrast, there was no effect on the radiosensitivity of HT-29 tumors expressing wild-type RAS. These results demonstrate that specific radiosensitization of tumors expressing activated RAS oncogenes can be obtained in vivo. (C) 2000 by Radiation Research Society.",
author = "Elizabeth Cohen-Jonathan and Muschel, {Ruth J.} and McKenna, {W. Gillies} and Evans, {Sydney M.} and George Cerniglia and Rosemarie Mick and Donna Kusewitt and Sebti, {Said M.} and Andrew Hamilton and Allen Oliff and Nancy Kohl and Gibbs, {Jackson B.} and Bernhard, {Eric J.}",
year = "2000",
month = "8",
language = "English (US)",
volume = "154",
pages = "125--132",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "2",

}

TY - JOUR

T1 - Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS

AU - Cohen-Jonathan, Elizabeth

AU - Muschel, Ruth J.

AU - McKenna, W. Gillies

AU - Evans, Sydney M.

AU - Cerniglia, George

AU - Mick, Rosemarie

AU - Kusewitt, Donna

AU - Sebti, Said M.

AU - Hamilton, Andrew

AU - Oliff, Allen

AU - Kohl, Nancy

AU - Gibbs, Jackson B.

AU - Bernhard, Eric J.

PY - 2000/8

Y1 - 2000/8

N2 - Successful radiosensitization requires that tumor cells become more radiosensitive without causing an equivalent reduction in the survival of cells of the surrounding normal tissues. Since tumor cell radiosensitivity can be influenced by RAS oncogene activation, we have hypothesized that inhibition of oncogenic RAS activity would lead to radiosensitization of tumors with activated RAS. We previously showed in tissue culture that prenyltransferase treatment of cells with activated RAS resulted in radiosensitization, whereas treatment of cells with wild-type RAS had no effect on radiation survival. Here we ask whether the findings obtained in vitro have applicability in vivo. We found that treatment of nude mice bearing T24 tumor cell xenografts with farnesyltransferase inhibitors resulted in a significant and synergistic reduction in tumor cell survival after irradiation. The regrowth of T24 tumors expressing activated RAS was also significantly prolonged by the addition of treatment with farnesyltransferase inhibitors compared to the regrowth after irradiation alone. In contrast, there was no effect on the radiosensitivity of HT-29 tumors expressing wild-type RAS. These results demonstrate that specific radiosensitization of tumors expressing activated RAS oncogenes can be obtained in vivo. (C) 2000 by Radiation Research Society.

AB - Successful radiosensitization requires that tumor cells become more radiosensitive without causing an equivalent reduction in the survival of cells of the surrounding normal tissues. Since tumor cell radiosensitivity can be influenced by RAS oncogene activation, we have hypothesized that inhibition of oncogenic RAS activity would lead to radiosensitization of tumors with activated RAS. We previously showed in tissue culture that prenyltransferase treatment of cells with activated RAS resulted in radiosensitization, whereas treatment of cells with wild-type RAS had no effect on radiation survival. Here we ask whether the findings obtained in vitro have applicability in vivo. We found that treatment of nude mice bearing T24 tumor cell xenografts with farnesyltransferase inhibitors resulted in a significant and synergistic reduction in tumor cell survival after irradiation. The regrowth of T24 tumors expressing activated RAS was also significantly prolonged by the addition of treatment with farnesyltransferase inhibitors compared to the regrowth after irradiation alone. In contrast, there was no effect on the radiosensitivity of HT-29 tumors expressing wild-type RAS. These results demonstrate that specific radiosensitization of tumors expressing activated RAS oncogenes can be obtained in vivo. (C) 2000 by Radiation Research Society.

UR - http://www.scopus.com/inward/record.url?scp=17444454260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444454260&partnerID=8YFLogxK

M3 - Article

VL - 154

SP - 125

EP - 132

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 2

ER -